Learning objectives
- To describe the basics of the Neck Imaging Reporting and Data System (NI-RADS) classification.
- To learn common pitfalls that lead to wrong classification and management plan of patients with head and neck cancers (HNC).
- To learn some tips and tricks to optimize NI-RADS classification.
Background
NI-RADS was developed for follow-up imaging evaluation in patients with treated HNC.
It aims to provide numerical levels of suspicion for residual tumor or recurrence,
generate data-mineable reports and standardize approach with linked management recommendations.
Nevertheless,
accurate knowledge of common pitfalls is mandatory to avoid patient’s management errors.
Findings and procedure details
Findings and procedure details:
NI-RADS classification is based on the combination of morphological (CT,
MRI) and molecular (F-18-FDG PET) imaging.
In this poster,
along with the description of the four NI-RADS categories,
we present the most frequently made but avoidable pitfalls.
Errors in NI-RADS classification can be divided into those related to technical aspects (metal or motion artifacts,
PET resolution,
scan timing,
single imaging method),
normal (physiological F-18-FDG uptake) or tumor (low baseline F-18-FDG uptake,
necrosis) conditions and those related to treatment induced changes (inflammatory...
Conclusion
Accurate knowledge of typical post-treatment imaging patterns as well as of common pitfalls is mandatory to expend the use of NI-RADS,
thus allowing standardization of patients’ imaging report and care.
References
ADDIN EN.REFLIST [1] A.H.
Aiken,
T.J.
Rath,
Y.
Anzai,
B.F.
Branstetter,
J.K.
Hoang,
R.H.
Wiggins,
A.F.
Juliano,
C.
Glastonbury,
C.D.
Phillips,
R.
Brown,
P.A.
Hudgins,
ACR Neck Imaging Reporting and Data Systems (NI-RADS): A White Paper of the ACR NI-RADS Committee,
J Am Coll Radiol 15(8) (2018) 1097-1108.
[2] D.A.
Krieger,
P.A.
Hudgins,
G.K.
Nayak,
K.L.
Baugnon,
A.S.
Corey,
M.R.
Patel,
J.J.
Beitler,
N.F.
Saba,
Y.
Liu,
A.H.
Aiken,
Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma,
AJNR...